17 Nov Clinical trials enter a new digital era

By Ed Miseta, Clinical Leader

The life sciences industry has been undergoing a transformation. Its seen advancements in how therapies are developed and improvements in how the industry works together. One development that has helped the industry evolve is the shift to digital technologies. The COVID-19 pandemic forced companies to adopt decentralized technologies to enable remote trial execution. The shift introduced more technologies into the trial ecosystem, which has created challenges for companies.

A panel of experts at the Veeva R&D and Quality Summit Connect addressed this topic in a roundtable discussion. The panel consisted of Lorena Gomez of AbbVie, Staci McDonald of Celerion, Mayank Anand of GSK, and Mark Morais of Labcorp Drug Development.

The panel notes COVID forced companies to quickly adopt digital approaches, but drug developers are now trying to be more forward thinking. Digital technologies present pharma with the opportunity to make clinical studies more accommodating of sites and patients. A strategic enterprise plan will likely be required to make protocols simpler and easier to execute while facilitating digital approaches. Read more …